← Eichor
Study identifier: NCT06375278 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation

Condition: Cochlear Implants · Cochlear Implantation · Hearing Loss  ·  Sponsor: Restorear Devices LLC

PhaseNA
Planned participants54
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia for preservation of residual hearing in cochlear implant surgery. The main questions the trial aims to answer are: 1. Is mild therapeutic hypothermia safe for use during cochlear implantation? 2. Is mild therapeutic hypothermia effective at preserving residual hearing after cochlear implantation? Participants will receive mild therapeutic hypothermia therapy during cochlear implant surgery. Researchers will compare results from those receiving the therapy to those from a control group (individuals receiving no therapy).

This description comes directly from the study's public registry record.

Talk to the study team

Suhrud M Rajguru, Ph.D.  ·  801-641-8180  ·  srajguru@restorear.com

Curtis S King  ·  406-414-6278  ·  cking@restorear.com

Always discuss trial participation with your own doctor first.

Locations (1)

University of MiamiMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06375278